About dabigatran etexilate mesylate
Direct thrombin inhibitor anticoagulant
Used for
- Prevention of stroke and blood clots in nonvalvular atrial fibrillation
- Treatment and prevention of deep vein thrombosis and pulmonary embolism
- Prevention of clots after hip replacement surgery
Usual adult dose
Often 150 mg twice daily for atrial fibrillation or clot treatment; doses vary by indication, kidney function, and age.
Usual dose in children
For children aged 8 years and older with blood clots, weight-based doses are used; specialist supervision is required.
Common side effects
- Bleeding or bruising
- Indigestion, stomach pain, or nausea
- Anemia
- Rare serious allergic reactions
Important warnings
- Can cause serious or fatal bleeding.
- Kidney function affects dosing and suitability.
- Do not stop suddenly without medical direction; clot risk may increase.
- Capsules must be swallowed whole; opening or chewing increases bleeding risk.
Pregnancy
Generally avoided because of limited safety data and potential bleeding risks; use requires specialist assessment.
Breastfeeding
Breastfeeding is generally not recommended during treatment because transfer into milk and infant effects are uncertain.
Interactions
- Other anticoagulants or antiplatelet medicines increase bleeding risk.
- NSAIDs such as ibuprofen can increase bleeding.
- P-glycoprotein medicines, including ketoconazole or rifampin, can alter levels.
- Some seizure medicines, including carbamazepine, can reduce effectiveness.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.